Our results provide firm evidence for the efficacy of the applied regimen, with close to 80% of liver cancer patients achieving complete remission at the end of treatment.
The study linked below citing “dramatic” increase in overall survival in pediatric heptoblastoma patients is a classic good news/bad news oncology situation. The study indicates that kids live longer with this therapy regimen but the kids will also greatly increase the risk of side effects including hearing loss, heart damage, nutrapenia, nerve damage and others.
You have got to ask yourself if you can have your cake and eat it too? Can a pediatric heptoblastoma patient increase overall survival AND reduce the toxicity and risk of side effects from the cancer therapy?
Curcumin, thoroughly researched and shown to enhance the efficacy of cisplatin while reducing its toxicity, may be able to help. My point is that there are evidence-based non-conventional therapies that may be able to help. These are therapies that have not been researched and approved by the FDA.
I am both a cancer survivor and cancer coach. To learn more about evidence-based therapies to reduce the toxicty and collateral damage of chemotherapy, scroll down the page, post a question or comment and I will reply ASAP.
“Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence…The age of onset of liver cancer in children is related to tumor histology. Hepatoblastomas usually occur before the age of 3 years, and approximately 90% of malignant liver tumors in children aged 4 years and younger are hepatoblastomas.
The overall 5-year survival rate for children with hepatoblastoma is 70%,[10–12] but is only 42% for those with hepatocellular carcinoma. The 5-year survival for hepatocellular carcinoma may be dependent on stage; in an Intergroup chemotherapy study conducted in the 1990s, seven of eight stage I patients survived and less than 10% of stage III and IV patients survived.[3,13]”
“Background- The objective of this study was to establish the efficacy and safety of a new treatment regimen consisting of dose-dense cisplatin-based chemotherapy and radical surgery in children with high-risk hepatoblastoma…
The SIOPEL-4 trial addressed the question of whether increased dose density of cisplatin in the preoperative phase can improve the prognosis of children with high-risk, in particular metastatic, hepatoblastoma (panel). Our results provide firm evidence for the efficacy of the applied regimen, with close to 80% of patients achieving complete remission at the end of treatment. The proportion of patients with complete remission and the 3-year event-free and overall survival compare favourably with results of previous studies and suggest an improvement in the prognosis of children with high-risk hepatoblastoma.
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”